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Abstract
Wilms tumor protein (WT1) is a transcription factor selectively overexpressed in leukemias and cancers; clinical trials are
underway that use altered WT1 peptide sequences as vaccines. Here we report a strategy to study peptide-MHC interactions
by incorporating non-natural and photo-reactive amino acids into the sequence of WT1 peptides. Thirteen WT1 peptides
sequences were synthesized with chemically modified amino acids (via fluorination and photo-reactive group additions) at
MHC and T cell receptor binding positions. Certain new non-natural peptide analogs could stabilize MHC class I molecules
better than the native sequences and were also able to elicit specific T-cell responses and sometimes cytotoxicity to
leukemia cells. Two photo-reactive peptides, also modified with a biotin handle for pull-down studies, formed covalent
interactions with MHC molecules on live cells and provided kinetic data showing the rapid clearance of the peptide-MHC
complex. Despite ‘‘infinite affinity’’ provided by the covalent peptide bonding to the MHC, immunogenicity was not
enhanced by these peptides because the peptide presentation on the surface was dominated by catabolism of the complex
and only a small percentage of peptide molecules covalently bound to the MHC molecules. This study shows that non-
natural amino acids can be successfully incorporated into T cell epitopes to provide novel immunological, biochemical and
kinetic information.
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Introduction
Specific T cell mediated immune responses involve T-
lymphocytes that respond to linear peptide epitopes, typically
between 8 and 20 amino acids in length. The peptides recognized
by CD8+ T cells are 8–10 amino acids in length and are presented
by class I major histocompatibility complex (MHC) molecules on
the target cells. Class I MHC molecules have an affinity preference
for peptides with particular major anchor residues, usually at
amino acid positions 2 and 9. The stability of the peptide/MHC
(pMHC) complexes correlates generally with the strength of the T
cell response to the epitope.
Most cancer antigens are ‘‘self-antigens’’ expressed on normal
cells and sometimes overexpressed on cancer cells. Immunogenic
peptides derived from these tumor-associated proteins have been
used in therapeutic vaccination protocols. Advances in the
understanding of the cellular immune response to peptide antigens
and structural studies of the pMHC have led to different strategies
for improving cancer vaccines. One frequently studied antigen is
the Wilms tumor protein (WT1), a zinc-finger transcription factor
expressed during normal ontogenesis [1,2,3]. In adults, WT1
expression is limited to low levels in the nuclei of normal CD34+
hematopoietic stem cells, myoepithelial progenitor cells, renal
podocytes and some cells in the testis and ovaries [4,5,6]. The
WT1 gene product is over-expressed in hematological [7,8,9] and
solid malignancies [10], making it an attractive target for
immunotherapy. Short peptides derived from WT1 protein have
been identified that generate a WT1-specific cytotoxic response
[11,12,13,14,15,16].
The feasibility of targeting WT1 has resulted in different clinical
trials using four peptides with different adjuvants in the context of
HLA-A0201 and HLA-A2402. Several trials are currently testing
the WT1 235–243 natural sequence and modified sequence
[17,18,19] in patients who are HLA-A2402; another set of studies
tested the WT1 126–134 natural sequence [20] and modified
peptides in patients who are HLA-A0201 [21].
Overcoming the often weak immunogenicity of and tolerance to
tumor antigens may require appropriate modifications in the
peptide sequence to increase pMHC or the T cell receptor (TcR)
TcR-pMHC interactions; such changes should induce a more
robust immune response if cross-reactivity to the native sequence
was produced. One strategy used by our group and others is the
design of synthetic analog peptides with natural amino acid
substitutions at the anchor positions in the MHC molecule
[18,19,21] that increase affinity, stimulate greater T cell
recognition or break tolerance. Here we propose a new strategy
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into the CD8 peptide antigen. Incorporation of photo-reactive
amino acids into the peptide sequences may provide unique
opportunities to manipulate peptide-MHC binding interactions.
The added modification of a biotin handle on the peptide allows
kinetic studies of the peptide-MHC complex. Such non-natural
amino acids could also serve to improve affinity at the pMHC or
TcR recognition sites, break tolerance, or reduce catabolism of the
peptide. In the present study, the incorporated non-natural amino
acids into the sequence of WT1 peptides allowed us to determine if
these alterations would increase avidity of binding to MHC,
improve immunogenicity and result in cross-reactivity and
cytolytic activity against WT1 expressing cancer cells, and study
the MHC-peptide complex.
Materials and Methods
Peptides
Potentially immunogenic peptides were selected from the
Wilms’ tumor (WT1) protein [21] (Table 1). Structures of the
non-natural amino acids are shown in Figure 1. Peptides WT1 B,
WT1B-S1Y, WT1B-S1V, WT1 B 8mer, WT1B-L2LF3, WT1 J,
WT1J-C1Y and WT1J-M2Y were synthesized by Genemed
Synthesis Inc. (CA, USA) using fluorenylmethoxycarbonyl chem-
istry, solid phase synthesis and purified by high-pressure liquid
chromatography. The quality of the peptides was assessed by high-
performance liquid chromatography analysis, and the expected
molecular weight was observed using matrix-assisted laser
desorption mass spectrometry. Peptides were sterile and greater
than 70% pure. The peptides were dissolved in DMSO and
diluted in phosphate-buffered saline (PBS; pH 7.4) or saline to give
a concentration of 5 mg/ml and were stored at 280uC.
We synthesized the peptides: WT1B-S1VF3, WT1B-S1FF2,
WT1B-S1FA-bio, WT1B-L2FF3,WT1B-S1Fbz-bio, WT1J–W4WF,
WT1J-C1Fbz (Table 1) using solid phase synthesis, on a Wang
resin via automated synthesizer (PS3
TM Peptide Synthesizer,
Protein Technologies, Inc) using a single-coupling protocol. After
cleavage from the resin using Reagent R (TFA:thioanisole:ED-
T:anisole, 90:5:3:2), the peptides were purified by high-pressure
liquid chromatography (HPLC) on a reverse-phase C18 column
(ZORBAX 300SB-C189.4 mm625 cm, Agilent Technologies)
with a 0 to 98% gradient of acetonitrile containing 0.1%
trifluoroacetic acid (TFA). Peptide identity was verified by mass
spectrometry. Biotinylation was achieved by using a commercially
available Fmoc-L-glutamine amino acid containing biotin by way
of a polyethylene glycol linker (Calbiochem) during peptide
synthesis. Purities were greater than 90%.
Peptides WT1B-S1FA, and WT1J-C1FA (Table 1) were
synthesized by coupling the WT1B and WT1J 8-mers LGEQ-
QYSV and MTWNQMNL, respectively, to the F-moc-4-azido-L-
phenylalanine, using 0.4 M NMM/DMF as a coupling solution.
After removal of F-moc by adding 20% piperidine/DMF, final
deprotection and cleavage from the resin was done using Reagent
R. Peptide identity was verified by mass spectrometry.
Cell lines
TAP-deficient T2 cells were obtained from the American Type
Culture Collection (Rockville, MD). 697 CML cells (WT1+)a n d
SKLy-16 lymphoma cells (WT1-) were obtained from Sloan-
Kettering stocks. Cells were grown in RPMI 1640 medium
supplemented with 5% fetal bovine serum, 2 mM L-glutamine, b-
mercaptoethanol, penicillin (100 U/ml) and streptomycin (100 mg/
ml) ina humidified atmosphere containing 5%CO2 inan incubator.
Peptide binding assay
Peptide binding to HLA-A0201 was assessed using a flow
cytometry-based MHC stabilization assay [22], on the T2 cell line,
which has HLA-A0201 expression and is TAP deficient in
Figure 1. Chemical structures of the non-natural amino acids
used in this study.
doi:10.1371/journal.pone.0003938.g001
Table 1. Name and sequence* of the peptides.
Classification Of peptide Peptide name: ‘‘B’’ series Sequence: ‘‘B’’ series Peptide name: ‘‘J’’ series Sequence: ‘‘J’’ series
Native peptides WT1B SLGEQQYSV WT1 J CMTWNQMNL
WT1B 8mer LGEQQYSV WT1J 8mer MTWNQMNL
Heteroclitic peptides WT1B-S1Y YLGEQQYSV WT1J-C1Y YMTWNQMNL
WT1B-S1V VLGEQQYSV WT1J-M2Y CYTWNQMNL
Unnatural and photo-reactive
peptides
WT1B-S1FA FALGEQQYSV WT1J-C1FA FAMTWNQMNL
WT1B-S1FA-bio
WT1B-S1Fbz-bio
WT1B-L2 LF3
FALGEQ
bioQYSV
FbzLGEQ
bioQYSV
SLF3GEQQYSV
WT1J-C1Fbz FbzMTWNQMNL
WT1B-S1VF3 VF3LGEQQYSV WT1J-W4WF CMTWFNQMNL
WT1B-S1FF2 FF2LGEQQYSV
*FA=4-azido-L-phenylalanine; LF3=5,5,5-trifluoro-DL-leucine; VF3=4,4,4-trifluoro-DL-valine; FF2=3,4-difluoro-L-phenylalanine; WF=5-fluoro-DL-tryptophan; bio=biotin;
Fbz=4-benzoyl-phenylalanine.
doi:10.1371/journal.pone.0003938.t001
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binding of peptide in vitro was measured as the ability of
exogenously added peptides to stabilize the class I MHC/ b2-
microglobulin structure on the surface of the T2 cell line. Briefly,
T2 cells were incubated in 24-well flat bottom plates at 5610
5
cells/well in a 600 ml volume of serum-free medium with human
b2-microglobulin at a final concentration of 10 mg/ml with and
without peptides at concentrations between 50 and 1 mg/ml for
16 h at 37uC. Cells were then incubated with 5 mg/ml brefeldin A
(Sigma) for 2 h at 37uC. After washing twice with FACS buffer
(2% human serum in PBS), cells were incubated for 30 minutes in
the dark at 4uC with FITC labeled anti-human HLA-A2 antibody,
(BD Pharmingen
TM). Fluorescence was determined using a
Cytomics
TM FC 500, (Beckman Coulter) and analyzed using the
FlowJo program. Assays were run with a positive reference peptide
of high affinity (a decapeptide from the antigen S of the hepatitis B
virus, FLPSDYFPSV). For clarity, the reference binding curves are
not shown in the panel. Each concentration of peptide (1, 10 and
50 mg/ml) was assayed in triplicate wells. For the time course
experiments, 50 mg/ml of peptide was used and cells were
incubated for various times up to 24 hr before flow cytometric
assay to follow the loss of the peptide MHC complex from the cell
surface. Each experiment was done at least twice.
A different kinetic and quantitative assessment of peptide
binding was conducted using another flow cytometry assay in
which binding was measured using an anti-biotin mouse
monoclonal antibody conjugated to AlexaFluor 488 (Invitrogen).
In this assay, T2 cells were treated with indicated peptides for
various times, exposed to ultraviolet light as described earlier, then
washed twice with PBS containing 1% human serum. Then, in
aliquots of 10
5 cells in 100 ml volume of PBS containing 1%
human serum, cells were treated with 2.5 mg/ml of the anti-biotin
AlexFluor 488 conjugate for 20 minutes on ice in the dark. Cells
were washed twice in PBS then analyzed by flow cytometry.
Other experiments were done in which acid stripping of
peptides was used to measure residual peptides on the surface of
MHC molecules. Following UV light treatment, T2 cells were
washed twice with PBS containing 1% human serum. Cells were
re-suspended in stripping buffer (0.13 M citric acid, 0.06 M
sodium phosphate monobasic, pH 3.0, 1% BSA) for 120 seconds
on ice, then five volumes of neutralizing buffer were added
(0.15 M sodium phosphate monobasic, 1% BSA, pH 7.5) before
pelleting cells for 109 at 4 C at 1,200 rpm. Cells were then washed
twice in PBS with 2% BSA before staining for flow cytometry.
For peptide internalization studies, T2 cells were treated with
peptides as described above, then incubated for 2 hr at 37 degrees.
The cells were split into two pools and one was left untreated and
the other washed twice to remove unbound and non-internalized
peptides. Both pools of cells were then incubated and tested for
peptide bound to the cell surface at 4 and 22 hours.
In vitro immunization and human T-cell cultures
After Institutional Review Board approved informed consent,
peripheral blood mononuclear cells (PBMCs) from HLA-A0201
positive healthy donors were obtained by Ficoll-density centrifu-
gation. Dr. Bo Dupont and Ms. Alice Yeh of the Immunology
Program, Sloan-Kettering Institute generously provided the HLA
genomic typing of the cells for this study.
Monocytes were isolated from the donors using magnetically
isolated CD14+ (Milteny, CA, USA) positive fractions and used as
antigen presentation cells (APCs) in the first stimulation. Dendritic
cells were generated as follows: CD14 positive fractions were
cultured in RPMI 1640 medium supplemented with 1%
autologous plasma, previously heat-inactivated, 500 U/ml recom-
binant human interleukin IL-4 (R&D Systems, Minneapolis, MN,
USA) and 1000 U/ml recombinant human granulocyte-macro-
phage colony-stimulating factor (GM-CSF) (Immunex, Seattle,
WA, USA). After 2 and 4 days of incubation, part of the medium
was exchanged for fresh culture medium supplemented with IL-4
and GM-CSF, and culture was continued. On day 6, half of the
medium was exchanged for fresh medium and a maturation
cocktail was added: IL-4, GM-CSF, 400 IU/ml IL-1b (R&D
Systems), 1000 IU/ml IL-6 (R&D Systems), GM-CSF, 10 ng/ml
TNF- alpha (R&D Systems) and 1 mg/ml pGE2 (Sigma, St. Louis,
MO). On day 7, the cells were harvested and used as APCs for the
second stimulation.
T lymphocytes were isolated from the CD14 negative fractions
using a pan T cell isolation kit. Non T cells, i.e., B cells, NK cells,
DCs, monocytes, granulocytes and erythrocytes were indirectly
labeled by using a cocktail of biotin-conjugated antibodies against
CD14, CD16, CD19, CD36, CD56, CD-123 and Glycophorin A,
and anti-biotin microbeads MoAb (milteny CA, USA). CD8+
lymphocytes were isolated from the CD14 negative fractions using
CD8 microbeads (Milteny, CA, USA). Purity was typically more
than 98% on flow cytometry.
T lymphocytes (CD3+ or CD8+) were stimulated the first time
at a 5:1 effector:target (E:T) ratio with monocytes (CD14+), in
RPMI 1640 medium supplemented with 5% heat-inactivated
human autologous plasma with WT1 synthetic peptides at a
concentration of 20 ug/ml and b2 microglobulin (Sigma, St Louis,
MO, USA) at 5 ug/ml in 6-well plates in the presence of 10 ng/ml
recombinant human IL-15 (R&D Systems). After 7 days T cells
were restimulated using the dendritic cells generated the week
before at a 30:1 E:T ratio, together with WT1 synthetic peptides,
b2 microglobulin and IL-15 at the same concentrations used in the
first stimulation. After culture for 2–3 days fresh medium with IL-
15 was added. After the second stimulation T cells were stimulated
weekly using CD14+ or DCs as a target (10:1 or 30:1 E:T ratio
respectively) depending on the availability of cells together with
WT1 peptides, b2 microglobulin and IL-15 at the same
concentrations. After the second and following stimulations,
interferon (IFN)-c secretion of these cells was then examined by
ELISPOT.
IFN-c ELISPOT
HA-Multiscreen plates (Millipore, Burlington, MA, USA) were
coated with 100 ml of mouse anti-human IFN-c antibody (10 mg/
ml); clone 1-D1K, Mabtech, Sweden) in PBS, incubated overnight
at 4uC, washed with PBS to remove unbound antibody and
blocked with RPMI/autologous plasma for 2 h at 37uC. Purified
T cells (CD3+ or CD8+, more than 95% pure) were plated at a
concentration of 1610
5/well. T cells were stimulated with
0.5610
5 T2 cells per well (2:1 E:T ratio), or 1610
4 CD14+ cells
(10:1 E:T ratio) or 3.3610
3 DCs (30:1 E:T ratio) pulsed with
5 mg/ml of b2-microglobulin and various test peptides at 20 mg/
ml. Negative control wells contained APCs with or without T cells
or T cells alone plus irrelevant control peptide. Positive control
wells contained T cells with APC plus 10 mg/ml PHA (Sigma). All
conditions were done in triplicate. After incubation for 20 h at
37uC, plates were extensively washed with PBS/0.05% Tween and
100 ml/well biotinylated detection antibodies against human IFN-
c (2 mg/ml; clone 7-B6-1, Mabtech, Sweden) was added. Plates
were incubated for an additional 2 h at 37uC and spot
development was performed as described [23]. Spot numbers
were automatically determined with the use of a computer-assisted
video image analyzer with KS ELISPOT 4.0 software (Carl Zeiss
Vision, Germany).
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The presence of specific cytolytic T lymphocytes (CTLs) was
measured in a standard 4 h. chromium release assay as described
(22). Briefly, target cells were incubated with or without synthetic
peptides at 50 mg/ml overnight in the presence of b2-micro-
globulin at 5 mg/ml, after which they were labeled with 100 mCi
of Na2
51CrO4 (NEN Life Science Products Inc., Boston, MA,
USA) for 1 h at 37uC. After washing, target cells were resuspended
in complete media at 3610
4/ml and plated in a 96-well U-bottom
plate (Becton Dickinson NY) at 3610
3 cells/well with effecter cells
at effecter to target (E/T) ratios ranging from 100:1 to 10:1. All
conditions were performed in triplicate. Plates were incubated for
4 h at 37uCi n5 %C O 2. Supernatant fluids were harvested and
radioactivity was measured in a gamma counter. Percent specific
lysis was determined from the following formula: 1006((experi-
mental release-spontaneous release)/(maximum release-spontane-
ous release)). Maximum release was determined by lysis of targets
in 2.5% Triton X-100.
MHC-peptide photo-activation, cross-linking, and
western blot analysis
T2 cells were incubated overnight at 37uC in serum-free RPMI
medium in the absence (negative control) or presence of 50 mg/ml
of the photo-activatable peptides WT1B-S1FA–biotin and WT1B-
S1FBZ–biotin. Following incubation, cells were exposed to a 40S-
XX Sylvania 115 volt short wavelength UV bench lamp for 1 min
at a range of 5 cm at room temperature (azido moiety) or a
Rayonet 17/15W 120 V long wavelength UV box for 30 minutes
on ice (for benzophenone moiety). For the time-course experi-
ments, cells were incubated in 5% dialyzed FBS during peptide
incubation and given 26fresh media containing 5% dialyzed FBS
in RPMI following UV exposure. Cells were then transferred to
Eppendorf tubes and washed twice with phosphate-buffered saline
(PBS). Cell pellets were lysed in 1 ml of RIPA buffer containing
protease inhibitor cocktail (Roche) and incubated with 7 ul of 50%
slurry streptavidin bead solution (Pierce) for 1 hr at 4uC, then
washed 4 times with PBS supplemented with 0.1% SDS. The
streptavidin-protein complexes were boiled in 2 times SDS sample
buffer for 5 minutes (BioRad), resolved by SDS-PAGE, transferred
to a PVDF membrane, and blocked in Tris buffered saline (TBS)
containing 5% milk. The membrane was probed with a 1:250
dilution of an anti-HLA-A goat polyclonal antibody (Santa Cruz,
A-18) overnight at 4uC, washed twice with TBS containing 0.1%
Tween-20 (TBST), probed with an HRP-conjugated donkey anti-
goat IgG (Santa Cruz Biotechnology) at 1:5000 dilution in TBS
with 5% milk for 2 hours at room temperature, then developed
using a chemiluminescent substrate (Pierce).
Results
Selection of WT1 peptides and non-natural amino acids
We selected two native nonapeptides from the WT1 protein
(Table 1), WT1 J (235–243) and WT1 B (187–195) because we
and others have shown their ability to generate a T cell response,
either to the native sequence or to modified synthetic analog
peptides [16,17,18,19,21]. We focused generally on changes to
amino acids in position one as previous work [21] showed that
these changes had a large impact on MHC binding when anchor
residues were already present. Here we first employed non-natural
amino acids in an attempt to improve MHC binding and
immunogenicity. Fluorinated amino acids were of special interest
because fluorine and hydrogen are nearly isosteric and fluorination
generally causes only modest structural perturbation compared to
hydrocarbon analogues; however fluorocarbons have elevated
hydrophobicity. In general, canonical medium to high affinity
anchor motif peptides for MHC class I make use of long
hydrophobic amino acids to bind to the MHC anchor pockets,
so we hypothesized that increasing the hydrophobicity in the area
of the anchor residues could induce better binding and
immunogenicity [21]. The following fluorinated peptides were
synthesized (Table 1, Fig. 1): WT1B-L2LF3, WT1B-S1VF3,
WT1B-S1FF2 and WT1J-W4WF. In contrast with the other non-
natural amino acid sequences, which were modified in or near the
position 2 anchor residue, WT1J-W4WF has the fluorinated amino
acid substitution in position 4, which is not an anchor residue,
because hydrophobic structural elements on central regions may
play a critical role in eliciting CTL responses [24].
The non-natural azido-phenylalanine was of interest because
phenylalanine is a long hydrophobic amino acid that could induce
a better binding to the MHC anchor. The incorporation of azido
amino acids was an attractive modification because the azide
group has the ability to survive cellular metabolism [25] and is
photo-reactive. We hypothesized that photo-activation of the
azido group could be used to covalently lock the peptide into
amino acids present in the MHC pocket, thus providing ‘‘infinite
affinity’’ at the site. In this way, use of azido amino acids may
provide unique opportunities to manipulate peptide-MHC
binding interactions to study the effect of permanent occupation
of a peptide in the MHC binding site and also to allow kinetic
studies of the peptide-MHC complex by use of a biotin handle.
The following azido-peptides were synthesized (Table 1, Fig. 1):
WT1B-S1FA and WT1J-C1FA. We also prepared a second class of
photo-reactive peptides with a less labile reactive moiety,
benzophenone (WT1J-C1Fbz and WT1B-FBZ), for the same
purpose. 8-mers (WT1B 8mer and WT1J 8mer), peptides lacking
the first amino acid were also included, in order to compare their
MHC binding affinity to the several other analogs with changes at
position 1.
Binding of non-natural peptides to HLA-A0201 molecules
Peptide binding to HLA molecules is a prerequisite for peptide
presentation and T-cell recognition. As computer algorithm
binding prediction programs include only natural amino acids,
and are relatively inaccurate [22] we directly measured the
interaction between the non-natural peptides and the HLA-A0201
molecules using the T2 binding and stabilization assay (supple-
mental figures S1 and S2). A dose-response curve was done to get
measurements of relative avidity among peptides and a time
course of stabilization was done as this may better reflect
immunogenicity of the peptides.
Analogs of WT1 J. The non-natural analogs of WT1J were
analyzed in a time-course binding assay and a peptide
concentration dose-response assay. WT1J-C1FA bound well, in
its unreactive form and after UV irradiation activation as well. As
expected, the control 8-mer peptide lacking the first amino acid
showed no significant binding. In each experiment, an HBV
peptide with known high avidity was used as an internal control of
assay integrity. The fluorinated WT1J-W4WF showed the best
binding profile in both a time- and a dose-dependent manner
compared with WT1J and the rest of the J analogs. This was
surprising because the modification was not near an anchor
residue.
Analogs of WT1 B. Three out of the four non-natural analogs
improved the measured binding to the HLA-A0201 molecules,
compared to the native WT1B peptide. WT1B-S1Y, a natural
synthetic analog and the tri-fluoro WT1B-S1VF3 generally
showed the best binding profiles. The control WT1B 8mer
peptide showed weak binding. The photo-activatable analog of
Non-Natural WT1 Epitopes
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analog. After irradiating with UV light, WT1B-S1FA showed
slightly lower binding ability, which may have been due to
hydrolysis and loss of the peptides after irradiation. The more
stable photoreactive WT1B-Fbz-bio showed similar binding to
both the natural WT1B sequence and the synthetic analog WT1B-
S1Y. In all these experiments, the HBV peptide was used as an
assay integrity positive control and showed a binding index of 5–7
at the highest concentrations tested (data not shown).
Photo-activatable peptides bind to HLA-A0201 MHC
molecules
To demonstrate the ability of photo-reactive peptides to bind
covalently to HLA molecules in live cells, we determined whether
MHC molecules could be pulled down and identified in lysed cells
after incubation with the biotinylated peptides and UV irradiation.
T2 cells or KG-1 (negative control cells lacking the HLA-A0201
allele) were incubated with WT1B-S1FA-biotin photo active
peptide or media alone overnight to non-covalently bind empty
MHC class I molecules on the T2 cell surface. At 20 h, the
peptides were photo-activated to allow cross-linking to their target
proteins, then complexes were isolated and resolved on SDS-
PAGE and developed using anti-HLA western blot (Fig. 2).
Specific covalent association of the activated azido-peptide with
the HLA-A0201 on the cells was demonstrated (Fig. 2A, lane 4.)
HLA-A0201 negative control cells with peptide (lane 1) and HLA-
A0201 positive cells not exposed to peptide (lane 2) did not display
the HLA-A molecule upon western blot analysis. T2 cells treated
with WT1B-S1FA peptide, but not exposed directly to UV light
demonstrated a small amount of MHC, (lane 3) consistent with its
high avidity for the target. Ponceau stains showed no significant
other bands present. These results demonstrated that derivatives of
the WT1B sequence harboring photo-activatable residues are
capable of covalently binding HLA-A molecules on live cells
following exposure to UV light.
To determine the kinetics of the maintenance of the interaction
of the peptide-MHC complex, we repeated the experiment of
adding the photo-reactive peptide to the T2 cells followed by UV
exposure. Next, cells were incubated for 0, 18 and 24 h at 37uCt o
allow kinetic analysis of the complex (Fig. 2B). The peptide-MHC
complex was almost completely lost after 24 hours of incubation,
presumably due to catabolism of the peptide structure, as cleavage
of the biotin from the amino acid is unlikely.
Similarly, the other WT1B peptide derivative harboring a
benzophenone moiety rather than an aryl azide (WT1B-Fbz), also
demonstrated covalent binding to HLA following UV-induced
cross linking (Fig. 2C). This peptide retained a small portion of its
binding after 24 hours, but was nearly all lost after 48 hours,
suggesting a more robust cross-linking from the benzophenone-
containing peptide versus the azido-containing peptide (compare
panel 2B to 2C). Cells treated with WT1B-FBZ , but not exposed to
UV light did not demonstrate cross-linking of HLA-A molecules.
These data probably can be attributed to the greater inherent
stability of benzophenone moiety versus that of aryl azides in the
presence of background light [26]. These kinetics are in agreement
with the T2 HLA stabilization assay, which demonstrate that
following 24 h of incubation of cells at 37uC, the expression of the
peptide-MHC complex on the cell surface is significantly reduced
(supplemental figure S1).
Induction of a peptide specific T cell response as
detected by IFN-c assay
Purified CD8+ T cells from healthy donors were stimulated with
monocyte-DC antigen presenting cells pulsed with the amino acid
sequences containing non-natural amino acid analogs to test their
ability to generate peptide-specific CTLs. After two or three T cell
stimulations in vitro, an IFN-c ELISPOT assay was performed to
measure specific and cross-reactive responses.
Analogs of WT1 J. WT1J is a weak immunogen [21]. The
non-natural analogs of WT1 J were tested in vitro against HLA-
A0201 donors. We compared the WT1J native peptide with the
natural peptide analogs, WT1J-C1Y and WT1J-M2Y, and with
the non-natural peptide WT1J-W4WF. Under these conditions, all
three analog peptides generated T cell responses to themselves
above background, whereas the native J peptide did not (Fig. 3).
Importantly, the T cells generated in the presence of both the
natural heteroclitic analogs and the non-natural analog, WT1J-
W4WF, were able to recognize to varying degrees, the native
sequence of WT1J in the setting of HLA-A0201 class I molecules.
After three rounds of stimulations, WT1J-C1Y and WT1J-W4WF
were able to generate a robust immune response. We also tested
the immunogenicity of the photo-activatable WT1J-C1Fbz and
WT1J-C1FA peptides. Both showed a weak immune response that
was even lower after UV irradiation (data not shown). These data
are consistent with the T2 binding data.
Analogs of WT1 B. All of the peptides containing non-
natural amino acids (WT1B-L2LF3, WT1B-S1VF3, WT1B-S1FF2
and WT1B-S1FA) were able to generate specific-CTL that
recognized the immunizing peptide (Fig. 3). WT1B-S1FA also
showed cross-reactivity with the analog WT1B-S1Y, but none of
the T cells stimulated by any of the B series analogs showed cross-
Figure 2. HLA western blot following biotin-peptide pull-down.
Panel a. T2 or control cells were treated with reagents indicated below
overnight at 37uC and then were exposed or were not exposed to UV
light. Lysates were then resolved on SDS gels and blotted for the
presence of HLA-A. Lane 1: WT1B-S1FA in control HLA-A0201-negative
cells (KG-1); Lane 2: T2 cells without peptide; Lane 3: T2 cells and WT1B-
S1FA without UV irradiation; Lane 4: T2 cells and WT1B-S1FA plus 1 min
short wavelength UV irradiation; Lane 5: Positive control cells whole
lysate with antibody. Panel b. Following photo-activation of peptide, T2
cells were incubated for the times indicated on the gel, prior to lysis and
western blot analysis. Lane 1: Positive control cells with whole lysate
and antibody; Lane 2: T2 cells without peptide. Lanes 3–5: T2 cells and
WT1B-S1FA plus 1 min short wavelength UV incubated for 0, 18, and
24 hr before analysis. Panel c. Conducted as in panel ‘b’ but using the
WT1B-S1Fbz peptide. Lane 1: T2 cells without peptide; Lane 2: WT1B-
S1Fbz with no UVirradiation; Lanes 3–5: T2 cells and WT1B- S1Fbz plus
30 min long wavelength UV followed by incubation for 0, 24, and 48 hr
before analysis.
doi:10.1371/journal.pone.0003938.g002
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stimulated in vitro with the WT1J peptides shown in the X axis and then challenged with the peptides shown in the legend. The Y axis represents the
number of spots per 1610
5 CD8+ T cells.
doi:10.1371/journal.pone.0003938.g003
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demonstrated a comparable response to WT1B-S1Y, the natural
heteroclitic analog that has been described previously as a more
immunogenic peptide compared with the native sequence WT1B
[21].
Quantitative and kinetic analysis of peptide cross-linking
Although western blot analysis indicated that the photo-
activatable peptides WT1B-S1FBZ-bio and WT1B-S1FA-bio
covalently bound HLA molecules, photoactivation of these
peptides did not stimulate cytotoxic T cells (data not shown). To
further assess the reasons for this, we treated T2 cells with the
WT1B-S1FBZ-bio photo-activatable peptide for 16 hours then
exposed them to UV light and measured the amount of peptide
bound on the cell surface using an anti-biotin monoclonal
antibody conjugated to an AlexFluor 488 fluorophore. Exposure
to UV light did not significantly increase the amount of peptide
bound on the cell surface (Table 2A). Binding was specific for the
test peptide as compared to a control peptide containing just five
residues, and also harboring a benzophenone moiety and a biotin
handle.
This experiment was repeated with an additional acid-stripping
step to remove non-covalent peptide-HLA interactions following
exposure to UV light (Table 2B). The data confirmed that the
number of peptides cross-linked to HLA molecules was small.
We then performed a pulse-chase experiment in which we
treated cells for 2 hours with peptide, washed cells of unbound or
non-internalized peptide, and then followed the amount of peptide
bound to the surface after incubation for an additional 4 or
22 hours. Total peptide on the surface continued to fall over time
after washing, to background levels at the 22 hour time point,
suggesting that either the peptides were not being internalized
prior to binding to HLA molecules or they were not being re-
circulated and presented in HLA molecules on the surface after
internalization (Table 2C). Together, these data show that, in
addition to rapid catabolism of peptide-HLA complexes shown in
Figure 2, the low efficacy of cross-linking by the photo-activatable
peptides may hinder the production of adequate numbers of
‘‘infinite’’ affinity peptide-HLA complexes to generate potent
cytotoxic responses.
Peptides containing non-natural amino acids stimulate
cytolytic T cells
WT1J-C1Y is the natural heteroclitic analog that has been
described previously as a more immunogenic peptide compared
with the native sequence WT1J. Despite its high affinity for the
MHC and its ability to generate positive and cross-reactive
ELISPOT data, WT1J-C1Y has not shown cytotoxic activity
against WT1 expressing target cells except when pulsed with the
specific peptide [21]. We tested the CD8 T-cells after the third
stimulation with the non-natural peptide WT1J-W4WF in a
chromium-51 release assay using WT1 expressing cells and
peptide-pulsed target cell lines. CD8+ T cells generated in vitro
from HLA-A0201 donors were able to kill the 697 cell line (HLA-
A201+, WT1+), whether pulsed or not pulsed with the native
WT1J peptide (Figure 4). In addition, these CD8+ T cells did not
recognize SKLY16 cells (HLA-A201+, WT1-), unless they had
been pulsed with the native WT1J peptide or the non-natural
peptide WT1J-W4WF showing that this was a specific peptide
restricted response.
Discussion
Protein engineering by amino acid substitution has usually been
restricted to the 20 naturally occurring amino acids. Recently, the
incorporation of non-natural amino acids into proteins in living
cells has greatly expanded the types of amino acids available for
different applications in protein engineering and functional studies
[27,28]. Non-natural amino acids also have been introduced into
peptide-based vaccines to enhance catabolic stability because
natural antigenic peptides have short bioavailability as a
consequence of high susceptibility to serum or tissue proteases.
Altered sequences may also promote greater immunogenicity of
the peptide by providing higher affinity to MHC binding pocket
anchor residues or by breaking immune tolerance to the native
amino acid sequence, so long as cross-reactivity to the original
protein sequence can be preserved.
Our study shows that an amplified T cell response can be
achieved sometimes by use of non-natural amino acids in the
sequence of WT1 peptides. The peptides synthesized could elicit
an effective T cell response to themselves and were capable of
sometimes stimulating T-cell responses stronger than those of their
original native peptides. Moreover, T cells stimulated with the
peptide WT1J-W4WF were able to recognize the native WT1J
sequence and showed cytotoxicity against an HLA-A0201, WT1+
acute leukemia cell line. Whether the enhanced response is derived
from the location of the modification or its biochemical nature
cannot be determined from these studies.
In addition, we were able to construct peptides that had photo-
affinity labels incorporated into them, which allowed the peptides
to be covalently attached to the MHC molecules after binding.
Table 2. Peptide Binding Photoactivation and Kinetic studies.
A: Peptide binding following photoactivation
Sample Mean fluorescence
a
0 uM WT1B-S1Fbz 1.54
0 uM WT1B-S1Fbz+UV 2.68
1 uM Control Peptide 1.56
1 uM Control Peptide+UV 2.76
1 uM WT1B-S1Fbz 41.5
1 uM WT1B-S1Fbz+UV 43.2
B: Peptide binding following acid stripping
Sample Mean fluorescence
0 uM WT1B-S1Fbz 1.34
0 uM WT1B-S1Fbz+UV 2.62
1 uM Control Peptide 1.47
1 uM Control Peptide+UV 2.12
1 uM WT1B-S1Fbz 1.63
1 uM WT1B-S1Fbz+UV 2.59
C: Peptide Binding is not affected by Internalization
Sample Mean fluorescence
0 uM WT1B-S1Fbz 2.02
1 uM WT1B-S1Fbz 2 h 8.74
1 uM WT1B-S1Fbz 6 h 44.4
1 uM WT1B-S1Fbz 6 h+wash 6.69
1 uM WT1B-S1Fbz 24 h 23.4
1 uM WT1B-S1Fbz 24 h+wash 2.16
amean fluorescence data were similar to median fluorescence data.
doi:10.1371/journal.pone.0003938.t002
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of the peptide-MHC complex over 24 hours, a time comparable to
the turnover of high avidity peptides not bound covalently to
MHC. The covalently bound peptides, despite their ‘‘infinite’’
affinity for MHC, were not demonstrably more immunogenic,
which suggests that once a peptide has achieved sufficient affinity
for the MHC molecule, further improvements in immunogenicity
will be limited first by the natural catabolism of the complex and
ultimately by the recognition and cross-reactivity of the T cell.
Furthermore, the data indicated that a very small fraction of the
photoactive peptide was covalently bound. While few peptides
need to be bound to MHC generate T cell responses, it is possible
that a higher efficiency of labeling might yield a stronger response,
despite the catabolism noted.
There have been other reports of improvements of infectious
disease vaccine epitopes by altering the peptides with non-natural
amino acid substitutions, but the present work is the first to show
stimulation by such sequences of cross-reactive, cytolytic T cell
responses to a cancer self-antigen. Studies of anti-viral immunity
using an Epstein-Barr virus subdominant epitope derived from the
membrane protein LMP2 that represents the target of HLA-
A0201 restricted CTL responses, was improved by preparing an
analog carrying one amino acid substitution at a non-anchor
position that was highly sensitive to proteolysis. Three peptides
with higher enzymatic resistance were found that stimulate CTL
responses against the natural epitope [29]. In order to improve the
same epitope analogs containing cis- and/or trans-4-aminocyclo-
hexanecarboxylic acid (ACCA) replacing dipeptide units were
made. All peptides showed higher enzymatic resistance and some
trans-ACCA derivatives also stimulated CTL responses against the
natural epitope [30]. A biologically active peptide containing beta-
amino acids was also synthesized. Oligomers of 3-hydroxybutano-
ate and/or beta-homoalanine were incorporated in the central
part of HLA-B27 epitope of HIV gp 120, without impairing MHC
binding [31].
Other groups have replaced residues that are not essential for
MHC binding by non-natural amino acids that are not recognized
by T-cells, or that might be able to antagonize autoreactive T cell
clones in autoimmune diseases. In this setting, Krebs et al.
synthesized three peptides with aromatic amino acids (alfa-
naphthylalanine, beta-naphthylalanine or homophenylalanine) in
the middle part of a HLA-B27 restricted epitope enhancing the
binding of the peptide to their host MHC protein [32]. Recently in
an effort to increase the affinity of peptides for HLA-B2705 Jones et
al. synthesized two modified epitopes with a non-natural arginine
analogue at position 2. The modified peptides have decreased
ability to bind the HLA-B2705 molecules and were not recognized
by CD8+ T cells [33].
A few studies have incorporated non-natural amino acids into T
cell epitopes for tumor vaccines. Webb et al. engineered an HLA-A2
restricted NY-ESO1 epitope, a tumor antigen of the cancer-testis
family, with modification of the C-terminal cysteine residue to 2-
aminoisobutyric acid, a cysteine iso-stereomer, that prevented the
dimerization resulting from oxidation of this residue, and this
modification did not affect HLA-A2 peptide stability, nor CTL
recognition [34]. The same group incorporated beta-amino acids
into peptides to decrease proteolysis [35]. Guichard et al. also
synthesized a melanoma MART-127–35 analogue with beta-amino
acid at the putative TcR contact residues improving HLA-A2
binding [36]. Guichard and other groups have being using D-
amino acids that produce retro-inverso analogues that have the
direction of the peptide bonds reversed. Retro-inverso peptides are
not susceptible to proteolytic degradation by naturally occurring
peptidases, and show significantly improved bioavailability [37].
Quesnel et al. introduced backbone modifications, aminomethylene
(CH2-NH) surrogate into the same melanoma peptide MART-
127–35. Five analogs bound MHC more efficiently than the parent
peptide and two were recognized by one melanoma-specific T cell
clone [38]. Most recently Douat-Casassus et al. have modified the
central amino acids of the melanoma MART-126–35 peptide using
nonpeptidic units in order to stimulate a stronger T-cell response.
Two compounds had high affinity for the HLA molecule and
stimulated several Melan-A/MART-1 specific T-cell clones [24].
In conclusion, the incorporation of appropriate non-natural
chemical entities into peptide-based vaccines for cancer immuno-
therapy may improve biological activity and provide new
information on peptide processing. Modification of the tumor
antigenic peptides at the anchor positions can enhance MHC
binding while modification of TcR contact residues can enhance
CTL responses. In this paper we have shown the successful
incorporation of non-natural amino acids into T cell epitopes in
both the anchor and TcR binding positions. The incorporation of
a fluorine in a TcR binding position has generated a peptide that
elicits a better immune response than the native sequence, which
was able to recognize and kill WT1+ cancer cells. Photo-reactive
analogs were also capable of covalently attaching to the MHC
carrier, but this modification did not enhance immunogenicity
because the half-life of the peptide in the MHC was dominated by
the catabolism of the complex and the level of covalent interaction
was low. Thus chemical modifications may provide alternative
pathways for the rational design of peptides with applications in
anti-tumor specific immunotherapy and in vaccine development.
Figure 4. Cytotoxicity assay with CD8 T cells from an HLA-A0201 donor after three stimulations in vitro. The assay was conducted as
described in Materials and Methods. The X axis shows different ratios between T cells to target cells. The targets and the peptides used to pulse them
are shown in the legend. The Y axis shows percentage of cytotoxicity.
doi:10.1371/journal.pone.0003938.g004
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Figure S1 T2 stabilization assay using peptides derived from
WT1J. The assay was conducted as described in Material and
Methods, with each panel representing a different experiment.
Sequences of the peptides are shown in Table 1. The Y axis shows
the mean fluorescence or the binding Index, that is the ratio
between the median fluorescence with the peptide tested divided
by median fluorescence with irrelevant peptide. Mean fluorescence
was used for time course studies as the indices became low at the
later time points with loss of MHC. The X axis show the time-
points of incubation of the peptide tested or the different
concentrations of the peptide tested. 1 min refers to UV
irradiation of the peptide for 1 min after adding it to the cells.
Found at: doi:10.1371/journal.pone.0003938.s001 (5.71 MB TIF)
Figure S2 T2 stabilization assay using peptides derived from
WT1B. The assay was conducted as described in Fig. 1, with each
panel representing a different experiment. Sequences of the
peptides are shown in Table 1.
Found at: doi:10.1371/journal.pone.0003938.s002 (5.61 MB TIF)
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